

---

**MSD**

Shire Park  
Welwyn Garden City  
Hertfordshire  
AL7 1TW

Tel: [REDACTED]  
Fax: [REDACTED]

17<sup>th</sup> June 2010

Dear Dr Carole Longson,

**RE: Appraisal Consultation Document (ACD). Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (part review of technology appraisal guidance 75 and 106)**

MSD welcomes this opportunity to respond to the Appraisal Consultation Document.

Overall we are pleased with the preliminary guidance, and are confident that the ACD reflects the best interests of patients and the NHS in ensuring treatment choice and appropriate use of peginterferon and ribavirin. On this basis, it is our view that the provisional recommendations are sound and constitute a suitable basis for the preparation of guidance to the NHS.

MSD is confident that the relevant comparators have been taken account and that the summaries of clinical and cost effectiveness are accurate. MSD is not aware of any aspects of the recommendations which would need particular consideration to ensure that unlawful discrimination does not takes place.

Sincerely,

[REDACTED]

[REDACTED]

MSD

---